tirzepatide obstructive sleep apnea fda approval 2024 Zepbound (tirzepatide) is now FDA-approved as the first medication for (OSA) in adults with obesity. It works by reducing body weight, which helps improve breathing during Zepbound® Approved to Treat Obstructive

Common adverse reactions reported in over 5% of patients treated with semaglutide include: Nausea Vomiting Diarrhea Abdominal pain Constipation Call your healthcare provider immediately if you experience any signs of an allergic reaction, including wheezing, chest tightness, fever, itching, bad cough, blue skin color, severe behavioral problems, chest pain or pressure, fast heartbeat, severe dizziness, passing out, nervousness and excitability, severe headache, or fits or swelling of the face, lips, tongue, or throat, How to reduce semaglutide side effects Your provider may start your weekly injections at a low dose and gradually increase to the prescribed dosage to minimize potential side effects

However, the absence of burping does not mean the medication is not working, as individual experiences with side effects vary considerably

(3) Its easy to understand why many people see growth hormone therapy as the fountain of youth

Patients with high-responding genetic profiles may reach goals on lower doses, while those with less-responsive variants can switch early to dual-compound protocols like GLP-Squaredavoiding wasted time and unnecessary dose escalation based on guesswork